1. Signaling Pathways
  2. Epigenetics
    JAK/STAT Signaling
    Protein Tyrosine Kinase/RTK
    Stem Cell/Wnt
  3. JAK

JAK

Janus kinase

Janus kinase (JAK) is a family of intracellular, nonreceptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway. Since members of the type I and type II cytokine receptor families possess no catalytic kinase activity, they rely on the JAK family of tyrosine kinases to phosphorylate and activate downstream proteins involved in their signal transduction pathways. The receptors exist as paired polypeptides, thus exhibiting two intracellular signal-transducing domains. JAKs associate with a proline-rich region in each intracellular domain, which is adjacent to the cell membrane and called a box1/box2 region. After the receptor associates with its respective cytokine/ligand, it goes through a conformational change, bringing the two JAKs close enough to phosphorylate each other. The JAK autophosphorylation induces a conformational change within itself, enabling it to transduce the intracellular signal by further phosphorylating and activating transcription factors called STATs. The activated STATs dissociate from the receptor and form dimers before translocating to the cell nucleus, where they regulate transcription of selected genes.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-124727
    ZT55
    Inhibitor 99.51%
    ZT55 is an orally active and highly-selective JAK2 inhibitor with an IC50 value of 0.031 μM. ZT55 inhibits the proliferation of JAK2V617F-expressing HEL cell lines and induces apoptosis and cycle arrest. ZT-55 also effectively inhibits the growth of HEL xenograft tumours in a mice model. ZT-55 can be used in studies of myeloproliferative neoplasms, polycythemia vera and primary thrombocythemia.
    ZT55
  • HY-40354S
    Tofacitinib-13C3
    Inhibitor
    Tofacitinib-13C3 is the 13C-labeled Tofacitinib. Tofacitinib is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively.
    Tofacitinib-<sup>13</sup>C<sub>3</sub>
  • HY-170360
    UCB9386
    Inhibitor
    UCB9386 is the selective and brain penetrant inhibitor for Nuak1 with a pIC50 of 10.1. UCB9386 inhibits Nuak2 and Kak2 with an inhibition rate of ca. 50% at 10 nM.
    UCB9386
  • HY-18300S
    Filgotinib-d4
    Inhibitor
    Filgotinib-d4 is the deuterium labeled Filgotinib. Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.
    Filgotinib-d<sub>4</sub>
  • HY-15315S1
    Baricitinib-d3
    Inhibitor ≥99.0%
    Baricitinib-d3 is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.
    Baricitinib-d<sub>3</sub>
  • HY-13450
    ZM 449829
    Inhibitor 99.73%
    ZM 449829 is a potent, selective and ATP competitive inhibitor of JAK3, with a pIC50 of 6.8. ZM 449829 will be useful pharmacological tools for the investigation of the JAK3.
    ZM 449829
  • HY-50859
    Ruxolitinib sulfate
    Inhibitor
    Ruxolitinib sulfate (INCB018424 sulfate) is the first potent, selective JAK1/2 inhibitor to enter the clinic with IC50s of 3.3 nM/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3.
    Ruxolitinib sulfate
  • HY-160144S1
    (S)-Lomedeucitinib
    Control 99.09%
    (S)-Lomedeucitinib ((S)-BMS-986322) is a S-enantiomer of Lomedeucitinib (HY-160144S). Lomedeucitinib is a tyrosine protein kinase (TYK2) inhibitor.
    (S)-Lomedeucitinib
  • HY-18300R
    Filgotinib (Standard)
    Inhibitor
    Filgotinib (Standard) is the analytical standard of Filgotinib. This product is intended for research and analytical applications. Filgotinib (GLPG0634) is a selective and orally active JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.
    Filgotinib (Standard)
  • HY-18315
    Bayer-18
    Inhibitor
    Bayer-18 is an inhibitor for TYK2. Bayer-18 inhibits the viability of ALCL cell K299, SR786, Mac1 and Mac2a with IC50 of 2-3 µM, and induces apoptosis in K299 and SR786.
    Bayer-18
  • HY-107595
    SD-1008
    Inhibitor 99.10%
    SD-1008 is a potent JAK inhibitor. SD-1008 inhibits tyrosyl phosphorylation of STAT3, JAK2 and Src. SD-1008 also reduces STAT3-dependent luciferase activity. SD-1008 enhances apoptosis induced by Paclitaxel in ovarian cancer cells via directly blocking the JAK-STAT3 signaling pathway.
    SD-1008
  • HY-19569A
    Upadacitinib tartrate tetrahydrate
    Inhibitor
    Upadacitinib (ABT-494) tartrate tetrahydrate is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib tartrate tetrahydrate displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib tartrate tetrahydrate can be used for several autoimmune disorders research.
    Upadacitinib tartrate tetrahydrate
  • HY-145336
    JAK1/TYK2-IN-1
    Inhibitor
    JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 (IC50 = 29 and 41 nM respectively).
    JAK1/TYK2-IN-1
  • HY-100754A
    Ritlecitinib (malonate)
    Inhibitor
    Ritlecitinib (PF-06651600) malonate is an orally active and selective JAK3 inhibitor with an IC50 of 33.1 nM. Ritlecitinib (malonate) can be used for the research of inflammatory and autoimmune diseases.
    Ritlecitinib (malonate)
  • HY-19568A
    Peficitinib hydrobromide
    Inhibitor
    Peficitinib (ASP015K) hydrobromide is an orally active JAK inhibitor, with IC50s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.
    Peficitinib hydrobromide
  • HY-130247C
    Flonoltinib sulfate
    Inhibitor
    Flonoltinib maleate is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib maleate has anti-cancer activity.
    Flonoltinib sulfate
  • HY-W394903R
    GS-829845 (Standard)
    Inhibitor
    Isatin (Standard) is the analytical standard of Isatin. This product is intended for research and analytical applications. Isatin (Indoline-2,3-dione) is a potent inhibitor of monoamine oxidase (MAO) with an IC50 of 3 μM. Also binds to central benzodiazepine receptors (IC50 against clonazepam, 123 μM). Also acts as an antagonist of both atrial natriuretic peptide stimulated and nitric oxide-stimulated guanylate cyclase activity. Shows effect on the serotonergic system.
    GS-829845 (Standard)
  • HY-159528
    Girocitinibum
    Inhibitor
    Girocitinibum (Girocitinib) is a Janus kinase inhibitor, with anti-inflammatory effect.
    Girocitinibum
  • HY-159536
    Frevecitinibum
    Inhibitor
    Frevecitinibum (Frevecitinib) is a Janus kinase inhibitor, with anti-inflammatory effect.
    Frevecitinibum
  • HY-111749
    JAK-IN-4
    Inhibitor
    JAK-IN-4 is a proagent of a JAK inhibitor, effective in murine collagen induced arthritis model.
    JAK-IN-4
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.